| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Wednesday, 2025-05-14. Here's what investors need to know before the announcement.
Analysts estimate that ADC Therapeutics will report an earnings per share (EPS) of $-0.38.
Anticipation surrounds ADC Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
During the last quarter, the company reported an EPS beat by $0.10, leading to a 1.97% drop in the share price on the subsequent day.
Here's a look at ADC Therapeutics's past performance and the resulting price change:
| Quarter | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.35 | -0.39 | -0.44 | -0.56 |
| EPS Actual | -0.25 | -0.28 | -0.25 | -0.38 |
| Price Change % | -2.0% | 0.0% | -6.0% | 9.0% |
Shares of ADC Therapeutics were trading at $1.34 as of May 12. Over the last 52-week period, shares are down 68.64%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
To track all earnings releases for ADC Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ADCT
